Shenzhen-based Xtalpi, an AI-powered drug discoverer, announced Tuesday it has partnered with U.S. pharmaceutical giant Eli Lilly in a deal worth up to $250 million to unearth potential medicines for an undisclosed disease.
Xtalpi said the drug candidates will target a disease that currently has no medicine available. Under the collaboration, Xtalpi is set to deliver a novel drug compound, which Eli Lilly will pursue clinical trials and commercialization, according to a statement.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased